NCT02637999View on ClinicalTrials.gov

Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 13, 2014

Primary Completion Date

January 21, 2016

Study Completion Date

January 21, 2016

Conditions
Chronic Hepatitis D Infection
Interventions
DRUG

PEG IFN alfa-2a

DRUG

Myrcludex B

Sponsors

Lead Sponsor

Hepatera Ltd.
All Listed Sponsors
lead

Hepatera Ltd.

INDUSTRY

NCT02637999 - Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection | Biotech Hunter | Biotech Hunter